Ipamorelin vs Tesamorelin
Head-to-head comparison of Ipamorelin and Tesamorelin for research applications. Both peptides are studied for Body Composition, but they differ significantly in mechanism and evidence level.
Side-by-Side Comparison
| Attribute | Ipamorelin | Tesamorelin |
|---|---|---|
| Category | Growth Hormone Secretagogue | Growth Hormone Secretagogue |
| Mechanism | Ipamorelin (sequence: Aib-His-D-2Nal-D-Phe-Lys-NH2) selectively binds to the Growth Hormone Secretagogue Receptor (GHS-R1a) on anterior pituitary somatotroph cells, increasing cAMP and activating protein kinase A to promote pulsatile GH secretion. | Tesamorelin binds to and stimulates human GRF (growth hormone-releasing factor) receptors on the anterior pituitary with similar potency as endogenous GRF, stimulating synthesis and release of endogenous growth hormone. |
| Evidence Rating | D — Preclinical | A — FDA Approved |
| Clinical Status | Research-only / Not approved for human use | FDA-approved (Egrifta SV 2019, Egrifta WR March 2025) for HIV-associated lipodystrophy |
| Safety Profile | Widely regarded as the mildest GHS available; minimal side effects in published animal and human studies; Common: mild temporary "head rush" or flushing immediately after injection due to sudden vasodilation | Headache, nausea, and flu-like symptoms reported; May increase blood glucose -- monitoring recommended in diabetics |
| Molecular Weight | ~711.9 g/mol | ~5135.9 g/mol |
| Half-Life | ~2 hours | ~26–38 minutes |
Overview
Ipamorelin and Tesamorelin are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, and safety profiles to help researchers understand the key differences and overlaps.
Ipamorelin — Mechanism & Evidence
Ipamorelin is the most selective growth hormone secretagogue (GHS) available, a synthetic pentapeptide (MW ~711.86 g/mol, formula C38H49N9O5) that stimulates pulsatile GH release from the pituitary gland without significantly affecting cortisol, prolactin, or appetite. It is widely regarded as the mildest GHS, making it popular in anti-aging, body composition, and recovery contexts. However, research on ipamorelin is limited, and it is not FDA-approved for any indication.
Key claims: Increases growth hormone levels; Improves body composition; Improves sleep quality.
Tesamorelin 10mg
10mg
Tesamorelin — Mechanism & Evidence
It stimulates endogenous GH and IGF-1 production. Phase 3 trials demonstrated significant visceral fat reduction with a generally well-tolerated safety profile over 26 weeks of therapy.
Key claims: Reduces visceral adipose tissue in HIV lipodystrophy; Increases skeletal muscle area and density; Effective on INSTI-based HIV regimens.
Shared Research Applications
Both peptides are studied for: Body Composition.
Ipamorelin is also researched for: Anti-Aging, Sleep.
Tesamorelin is also researched for: no additional unique applications.
Safety Considerations
Ipamorelin: Widely regarded as the mildest GHS available; minimal side effects in published animal and human studies Common: mild temporary "head rush" or flushing immediately after injection due to sudden vasodilation GH-related effects: joint discomfort, mild water retention (1-3 lbs), transient blood glucose elevation in 5-25% of users, usually resolving within 2-4 weeks
Tesamorelin: Headache, nausea, and flu-like symptoms reported May increase blood glucose -- monitoring recommended in diabetics FDA pregnancy category X -- tesamorelin can harm an unborn baby or cause birth defects
Shop Research Peptides
Tesamorelin 10mg
10mg
BPC-157 5mg
5mg
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
GHK-Cu 50mg
50mg
BPC-157 10mg
10mg
Tirzepatide 10mg
10mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
Tesamorelin vs Ipamorelin: Evidence, Uses, Risks
This article compares tesamorelin and ipamorelin based on published human evidence, highlighting what is known about their uses and risks and where direct comparative data is missing.
Tesamorelin vs CJC-1295: Evidence Gaps and Data
No head-to-head trial compares tesamorelin and CJC-1295. Existing evidence is analytical, not clinical, leaving efficacy claims unsupported.
CJC-1295 and Ipamorelin: Human Evidence and Limits
This reference separates what human trials, animal models, and analytical chemistry show about CJC-1295 and ipamorelin from vendor marketing, assessing the strength of the human evidence base and combination-specific safety data.
Peptide Tools
Follow Research Updates
Get new research pages, product updates, tool releases, and quality resources from Volta.
Subscribe